Metformin: from mechanisms of action to therapies.

By M. Foretz, B. Guigas, L. Bertrand, Michael Pollak, B. Viollet. Cell Metabolism, 2014

1,386 citations recorded by the source corpus.

Metformin is currently the first-line drug treatment for type 2 diabetes. Besides its glucose-lowering effect, there is interest in actions of the drug of potential relevance to cardiovascular diseases and cancer. However, the underlying mechanisms of action remain elusive. Convincing data place energy metabolism at the center of metformin's mechanism of action in diabetes and may also be of importance in cardiovascular diseases and cancer. Metformin-induced activation of the energy-sensor AMPK is well documented, but may not account for all actions of the drug. Here, we summarize current knowledge about the different AMPK-dependent and AMPK-independent mechanisms underlying metformin action.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/c05cafff5e4e1be3309ef17e2ba9198356ed7f97

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Sriram Gubbi
2. Nir Barzilai
3. Ameya Sadguru Kulkarni

In Molecular Biology

1. Sriram Gubbi
2. Nir Barzilai
3. Ameya Sadguru Kulkarni

Citations in the corpus

• Benefits of Metformin in Attenuating the Hallmarks of Aging (2020, background): “The downstream effect of mitochondrial complex I inhibition is directly evident from the increase in cytoplasmic AMP:ATP and ADP:ATP ratios, which in turn leads to phosphorylation and activation of AMPK (Foretz et al. 2014).”
• Metformin as a Tool to Target Aging (2016, neutral): “For example, an attractive explanation suggests (Foretz et al., 2014) that the primary action of metformin is to inhibit mitochondrial complex 1.”